Skip to main content

Table 2 Base case results for deterministic and probabilistic analyses: pembrolizumab vs DTIC

From: Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong

Model EstimatesDTICPembrolizumabDifference
Deterministic sensitivity analysis: mean
 Effectiveness (not discounted)
  Progression-free life years0.612.361.75
  Post progression life years2.135.483.34
  Life years2.747.835.09
  QALYs1.646.34.7
 Effectiveness discounted
  QALYs1.644.282.64
 Costs discounted, $
  Medication costs10,24986,93776,688
  Drug administration costs9591693735
  AE costs92863771
  Additional costs of care34,77951,63816,859
  Total46,079141,13195,052
 Cost effectiveness, $
  Incremental cost per LY gained  18,668
  Incremental cost per QALY gained  35,993
Probabilistic sensitivity analysis: mean (95% class interval)
 Effectiveness discounted
  LYs2.77 (1.42, 4.41)7.82 (7.40, 8.21)5.05 (3.37, 6.49)
  QALYs1.65 (0.86, 2.59)4.27 (4.06, 4.48)2.62 (1.66, 3.46)
 Costs discounted, $
  Total costs47,124 (35,410, 62,214)140,612 (127,407, 156,590)93,488 (80,879, 105,870)
 Cost Effectiveness, $
  Incremental cost per LY gained  18,510 (14,450, 26,412)
  Incremental cost per QALY gained  35,681 (27,509, 53,489)